全球慢性特發性便秘治療市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

全球慢性特發性便秘治療市場的需求預計將從2023年的120.4億美元達到2032年的近234.2億美元，2024-2032年研究期間的複合年成長率為7.67%。

慢性特發性便秘 (CIC) 是一種持續性胃腸道疾病，其特徵是排便次數少、排便困難和排便不完全的感覺，且沒有可識別的根本原因。它影響了很大一部分人口，導致不適和生活品質受損。當排除了便秘的常見原因（例如潛在的健康狀況或藥物副作用）後，即可診斷出 CIC。慢性特發性便秘的治療通常包括改變生活方式、改變飲食以及旨在改善腸道功能和緩解症狀的藥物。治療選擇包括瀉藥、大便軟化劑和增強胃腸蠕動的藥物。 CIC 的管理根據患者的個別需求進行量身定做，並考慮症狀嚴重程度和對先前治療的反應等因素。

市場動態

由於人口老化、久坐的生活方式和導致胃腸道問題的飲食習慣等因素的推動，慢性特發性便秘的盛行率不斷增加，慢性特發性便秘的治療市場正在擴大。人們日益認知到 CIC 是一個重要的健康問題，這導致了人們的認知和診斷的提高，從而推動了對有效治療方案的需求。專門針對 CIC 潛在機制的新藥物的開發，例如促動力劑和增強腸道蠕動的藥物，為患者提供了更好的治療選擇。藥物配方和給藥系統的創新，包括緩釋配方和聯合療法，為更有效和更方便的治療創造了機會。

此外，對個人化醫療的日益重視為根據患者個體情況量身定做治療方法提供了機會。診斷技術的進步和對 CIC 病理生理學的更好理解推動了這一趨勢，從而實現更有針對性和更有效的治療。飲食調整、纖維補充劑和生物反饋療法等非藥物治療的日益普及是另一個成長動力。這些方法為慢性特發性便秘治療提供了補充選擇，並且可以納入綜合治療計劃中。增強患者對 CIC 和可用治療方案的認知有助於提高依從性並改善結果。遠距醫療和數位醫療解決方案的擴展也有助於更好地獲得 CIC 的護理和管理，特別是在服務不足的地區。然而，高昂的治療成本和某些療法的潛在副作用可能會阻礙慢性特發性便秘治療市場的成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球慢性特發性便秘治療市場的各個細分市場進行了包容性評估。慢性特發性便秘治療產業的成長和趨勢為本研究提供了整體方法。

市場區隔

慢性特發性便秘治療市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略家確定相應產品或服務的目標人群以及即將到來的機會。

按藥物類別

• 5-羥色胺-4 (5-Ht4) 受體激動劑（普蘆卡必利、其他）
• 鳥苷酸環化酶-C 激動劑（普萊卡那肽、利那洛肽）
• 瀉藥（匹可硫酸鈉、聚卡波非等）
• 興奮劑（比沙可啶、Senokot 等）
• 其他

依給藥途徑

• 口服
• 直腸
• 配銷通路
• 醫院藥房
• 零售藥局
• 網路藥局

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲慢性特發性便秘治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。慢性特發性便秘治療市場的主要參與者包括拜耳公司、艾爾建、Bausch Health、賽諾菲、武田製藥公司、Sebela Pharmaceuticals、Ironwood Pharmaceuticals Inc.、Albireo Pharma Inc.、Sucampo Pharmaceuticals Inc. (Mallinckrodt) 、Janssen Pharmaceuticals Inc.。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

• 報告說明
  • 客觀的
  • 目標受眾
  • 獨特的銷售主張 (USP) 和產品
• 研究範圍
• 研究方法
  • 市場研究過程
  • 市場研究方法論

第 2 章：執行摘要

• 市場亮點
• 全球市場概況

第 3 章：慢性特發性便秘治療 - 產業分析

• 簡介 - 市場動態
• 市場促進因素
• 市場限制
• 機會
• 產業動態
• 波特五力分析
• 市場吸引力分析
  • 按藥品類別分類的市場吸引力分析
  • 按給藥途徑進行的市場吸引力分析
  • 市場吸引力分析：按地區

第 4 章：價值鏈分析

• 價值鏈分析
• 原料分析
  • 原料清單
  • 原料廠商清單
  • 主要原物料價格走勢
• 潛在買家名單
• 行銷管道
  • 直效行銷
  • 間接行銷
  • 行銷通路發展趨勢

第 5 章：全球慢性特發性便秘治療市場分析：依藥物類別

• 按藥物類別概述
• 按藥物類別進行歷史和預測數據分析
• 5-羥色胺-4 (5-Ht4) 受體激動劑（普蘆卡必利、其他）
• 鳥苷酸環化酶-C 激動劑（普萊卡那肽、利那洛肽）
• 瀉藥（匹可硫酸鈉、聚卡波非等）
• 興奮劑（比沙可啶、Senokot 等）
• 其他

第 6 章：全球慢性特發性便秘治療市場分析：依給藥途徑

• 依給藥途徑概述
• 按給藥途徑進行歷史和預測資料分析
• 口服
• 直腸
• 配銷通路
• 醫院藥房
• 零售藥局
• 網路藥局

第 7 章：全球慢性特發性便秘治療市場分析：以地理位置

• 區域展望
• 介紹
• 北美銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 北美按細分市場銷售分析
  • 北美按國家銷售分析
  • 美國銷售分析
  • 加拿大銷售分析
  • 墨西哥銷售分析
• 歐洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 歐洲按細分市場銷售分析
  • 歐洲按國家銷售分析
  • 英國銷售分析
  • 法國銷售分析
  • 德國銷售分析
  • 義大利銷售分析
  • 俄羅斯銷售分析
  • 歐洲其他地區銷售分析
• 亞太地區銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 亞太地區按細分市場銷售分析
  • 亞太地區按國家銷售分析
  • 中國銷售分析
  • 印度銷售分析
  • 日本銷售分析
  • 韓國銷售分析
  • 澳洲銷售分析
  • 東南亞銷售分析
  • 亞太地區其他地區銷售分析
• 拉丁美洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 拉丁美洲按細分市場銷售分析
  • 拉丁美洲按國家銷售分析
  • 巴西銷售分析
  • 阿根廷銷售分析
  • 秘魯銷售分析
  • 智利銷售分析
  • 拉丁美洲其他地區銷售分析
• 中東和非洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 中東和非洲按細分市場銷售分析
  • 中東和非洲按國家銷售分析
  • 沙烏地阿拉伯銷售分析
  • 阿拉伯聯合大公國銷售分析
  • 以色列銷售分析
  • 南非銷售分析
  • 中東其他地區和非洲銷售分析

第 8 章：慢性特發性便秘治療公司的競爭格局

• 慢性特發性便秘治療市場競爭
• 夥伴關係/協作/協議
• 併購
• 新產品發布
• 其他發展

第 9 章：公司簡介

• 頂級公司市佔率分析
• 市場集中度
• Bayer AG
• 公司概況
• 公司收入
• 產品
• 最新動態
• Allergan
• 公司概況
• 公司收入
• 產品
• 最新動態
• Bausch Health
• 公司概況
• 公司收入
• 產品
• 最新動態
• Sanofi
• 公司概況
• 公司收入
• 產品
• 最新動態
• Takeda Pharmaceutical Company
• 公司概況
• 公司收入
• 產品
• 最新動態
• Sebela Pharmaceuticals
• 公司概況
• 公司收入
• 產品
• 最新動態
• Ironwood Pharmaceuticals Inc.
• 公司概況
• 公司收入
• 產品
• 最新動態
• Albireo Pharma Inc.
• 公司概況
• 公司收入
• 產品
• 最新動態
• Sucampo Pharmaceuticals Inc. (Mallinckrodt)
• 公司概況
• 公司收入
• 產品
• 最新動態
• Janssen Pharmaceuticals Inc. (Johnson & Johnson)
• 公司概況
• 公司收入
• 產品
• 最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

The global demand for Chronic Idiopathic Constipation Treatment Market is presumed to reach the market size of nearly USD 23.42 Billion by 2032 from USD 12.04 Billion in 2023 with a CAGR of 7.67% under the study period 2024-2032.

Chronic idiopathic constipation (CIC) is a persistent gastrointestinal condition featuring infrequent bowel movements, difficulty passing stools, and a sensation of incomplete evacuation, without an identifiable underlying cause. It affects a significant portion of the population, leading to discomfort & impaired quality of life. CIC is diagnosed when common causes of constipation, such as underlying health conditions or medication side effects, have been ruled out. Chronic idiopathic constipation treatment typically includes lifestyle modifications, dietary changes, and medications aimed at improving bowel function and alleviating symptoms. Therapeutic options include laxatives, stool softeners, and medications that enhance gastrointestinal motility. The management of CIC is tailored to individual patient needs, considering factors such as symptom severity and response to previous treatments.

MARKET DYNAMICS

The chronic idiopathic constipation treatment market is expanding due to the increasing prevalence of CIC, driven by factors such as aging populations, sedentary lifestyles, and dietary habits that contribute to gastrointestinal issues. The growing recognition of CIC as a significant health concern has led to increased awareness and diagnosis, thereby driving demand for effective treatment options. The development of new medications that specifically target the mechanisms underlying CIC, such as prokinetic agents and drugs that enhance gut motility, offers improved therapeutic options for patients. Innovations in drug formulations and delivery systems, including extended-release formulations and combination therapies, create opportunities for more effective and convenient treatments.

In addition, the rising emphasis on personalized medicine presents opportunities for tailored treatment approaches based on individual patient profiles. This trend is bolstered by progress in diagnostic technologies and a better understanding of the pathophysiology of CIC, allowing for more targeted and effective therapies. The increasing adoption of non-pharmacological treatments, such as dietary modifications, fiber supplements, and biofeedback therapy, is another growth driver. These approaches offer complementary options for chronic idiopathic constipation treatment and can be integrated into comprehensive treatment plans. Enhanced patient awareness about CIC and available treatment options contributes to higher adherence and improved outcomes. The expansion of telemedicine and digital health solutions is also facilitating better access to care and management of CIC, particularly in underserved regions. However, high treatment costs and potential side effects of some therapies may hinder chronic idiopathic constipation treatment market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Chronic Idiopathic Constipation Treatment. The growth and trends of Chronic Idiopathic Constipation Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Chronic Idiopathic Constipation Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

• Serotonin-4 (5-Ht4) Receptor Agonist (Prucalopride, Others)
• Guanylate Cyclase-C Agonist (Plecanatide, Linaclotide)
• Laxatives (Sodium Picosulphate, Polycarbophil, Others)
• Stimulants (Bisacodyl, Senokot, Others)
• Others

By Route of Administration

• Oral
• Rectal
• Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Chronic Idiopathic Constipation Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Chronic Idiopathic Constipation Treatment market include Bayer AG, Allergan, Bausch Health, Sanofi, Takeda Pharmaceutical Company, Sebela Pharmaceuticals, Ironwood Pharmaceuticals Inc., Albireo Pharma Inc., Sucampo Pharmaceuticals Inc. (Mallinckrodt), Janssen Pharmaceuticals Inc. (Johnson & Johnson). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. CHRONIC IDIOPATHIC CONSTIPATION TREATMENT - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Class
  • 3.7.2 Market Attractiveness Analysis By Route of Administration
  • 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY DRUG CLASS

• 5.1. Overview By Drug Class
• 5.2. Historical and Forecast Data Analysis By Drug Class
• 5.3. Serotonin-4 (5-Ht4) Receptor Agonist (Prucalopride, Others) Historic and Forecast Sales By Regions
• 5.4. Guanylate Cyclase-C Agonist (Plecanatide, Linaclotide) Historic and Forecast Sales By Regions
• 5.5. Laxatives (Sodium Picosulphate, Polycarbophil, Others) Historic and Forecast Sales By Regions
• 5.6. Stimulants (Bisacodyl, Senokot, Others) Historic and Forecast Sales By Regions
• 5.7. Others Historic and Forecast Sales By Regions

6. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 6.1. Overview By Route of Administration
• 6.2. Historical and Forecast Data Analysis By Route of Administration
• 6.3. Oral Historic and Forecast Sales By Regions
• 6.4. Rectal Historic and Forecast Sales By Regions
• 6.5. Distribution Channel Historic and Forecast Sales By Regions
• 6.6. Hospital Pharmacies Historic and Forecast Sales By Regions
• 6.7. Retail Pharmacies Historic and Forecast Sales By Regions
• 6.8. Online Pharmacies Historic and Forecast Sales By Regions

7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION TREATMENT MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2 North America By Segment Sales Analysis
  • 7.3.3 North America By Country Sales Analysis
  • 7.3.4 United States Sales Analysis
  • 7.3.5 Canada Sales Analysis
  • 7.3.6 Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2 Europe By Segment Sales Analysis
  • 7.4.3 Europe By Country Sales Analysis
  • 7.4.4 United Kingdom Sales Analysis
  • 7.4.5 France Sales Analysis
  • 7.4.6 Germany Sales Analysis
  • 7.4.7 Italy Sales Analysis
  • 7.4.8 Russia Sales Analysis
  • 7.4.9 Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2 Asia Pacific By Segment Sales Analysis
  • 7.5.3 Asia Pacific By Country Sales Analysis
  • 7.5.4 China Sales Analysis
  • 7.5.5 India Sales Analysis
  • 7.5.6 Japan Sales Analysis
  • 7.5.7 South Korea Sales Analysis
  • 7.5.8 Australia Sales Analysis
  • 7.5.9 South East Asia Sales Analysis
  • 7.5.10 Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2 Latin America By Segment Sales Analysis
  • 7.6.3 Latin America By Country Sales Analysis
  • 7.6.4 Brazil Sales Analysis
  • 7.6.5 Argentina Sales Analysis
  • 7.6.6 Peru Sales Analysis
  • 7.6.7 Chile Sales Analysis
  • 7.6.8 Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2 Middle East & Africa By Segment Sales Analysis
  • 7.7.3 Middle East & Africa By Country Sales Analysis
  • 7.7.4 Saudi Arabia Sales Analysis
  • 7.7.5 UAE Sales Analysis
  • 7.7.6 Israel Sales Analysis
  • 7.7.7 South Africa Sales Analysis
  • 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE CHRONIC IDIOPATHIC CONSTIPATION TREATMENT COMPANIES

• 8.1. Chronic Idiopathic Constipation Treatment Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9. COMPANY PROFILES OF CHRONIC IDIOPATHIC CONSTIPATION TREATMENT INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Bayer AG
  • 9.3.1 Company Overview
  • 9.3.2 Company Revenue
  • 9.3.3 Products
  • 9.3.4 Recent Developments
• 9.4. Allergan
  • 9.4.1 Company Overview
  • 9.4.2 Company Revenue
  • 9.4.3 Products
  • 9.4.4 Recent Developments
• 9.5. Bausch Health
  • 9.5.1 Company Overview
  • 9.5.2 Company Revenue
  • 9.5.3 Products
  • 9.5.4 Recent Developments
• 9.6. Sanofi
  • 9.6.1 Company Overview
  • 9.6.2 Company Revenue
  • 9.6.3 Products
  • 9.6.4 Recent Developments
• 9.7. Takeda Pharmaceutical Company
  • 9.7.1 Company Overview
  • 9.7.2 Company Revenue
  • 9.7.3 Products
  • 9.7.4 Recent Developments
• 9.8. Sebela Pharmaceuticals
  • 9.8.1 Company Overview
  • 9.8.2 Company Revenue
  • 9.8.3 Products
  • 9.8.4 Recent Developments
• 9.9. Ironwood Pharmaceuticals Inc.
  • 9.9.1 Company Overview
  • 9.9.2 Company Revenue
  • 9.9.3 Products
  • 9.9.4 Recent Developments
• 9.10. Albireo Pharma Inc.
  • 9.10.1 Company Overview
  • 9.10.2 Company Revenue
  • 9.10.3 Products
  • 9.10.4 Recent Developments
• 9.11. Sucampo Pharmaceuticals Inc. (Mallinckrodt)
  • 9.11.1 Company Overview
  • 9.11.2 Company Revenue
  • 9.11.3 Products
  • 9.11.4 Recent Developments
• 9.12. Janssen Pharmaceuticals Inc. (Johnson & Johnson)
  • 9.12.1 Company Overview
  • 9.12.2 Company Revenue
  • 9.12.3 Products
  • 9.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers: Impact Analysis
• Restraints: Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• Analysis By Drug Class (USD MN)
• Serotonin-4 (5-Ht4) Receptor Agonist (Prucalopride, Others) Market Sales By Geography (USD MN)
• Guanylate Cyclase-C Agonist (Plecanatide, Linaclotide) Market Sales By Geography (USD MN)
• Laxatives (Sodium Picosulphate, Polycarbophil, Others) Market Sales By Geography (USD MN)
• Stimulants (Bisacodyl, Senokot, Others) Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Analysis By Route of Administration (USD MN)
• Oral Market Sales By Geography (USD MN)
• Rectal Market Sales By Geography (USD MN)
• Distribution Channel Market Sales By Geography (USD MN)
• Hospital Pharmacies Market Sales By Geography (USD MN)
• Retail Pharmacies Market Sales By Geography (USD MN)
• Online Pharmacies Market Sales By Geography (USD MN)
• Global Chronic Idiopathic Constipation Treatment Market Sales By Geography (USD MN)
• North America Market Analysis (USD MN)
• United States Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate By Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Chronic Idiopathic Constipation Treatment Report
• Market Research Process
• Market Research Methodology
• Global Chronic Idiopathic Constipation Treatment Market Size, By Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis By Drug Class
• Market Attractiveness Analysis By Route of Administration
• Market Attractiveness Analysis By Region
• Value Chain Analysis
• Global Market Analysis By Drug Class (USD MN)
• Serotonin-4 (5-Ht4) Receptor Agonist (Prucalopride, Others) Market Sales By Geography (USD MN)
• Guanylate Cyclase-C Agonist (Plecanatide, Linaclotide) Market Sales By Geography (USD MN)
• Laxatives (Sodium Picosulphate, Polycarbophil, Others) Market Sales By Geography (USD MN)
• Stimulants (Bisacodyl, Senokot, Others) Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Global Market Analysis By Route of Administration (USD MN)
• Oral Market Sales By Geography (USD MN)
• Rectal Market Sales By Geography (USD MN)
• Distribution Channel Market Sales By Geography (USD MN)
• Hospital Pharmacies Market Sales By Geography (USD MN)
• Retail Pharmacies Market Sales By Geography (USD MN)
• Online Pharmacies Market Sales By Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.